① Standard Chartered Bank joins 56 other companies as ESMA’s first MiCA registered entities


Standard Chartered Bank has obtained a MiCA passport. The European Securities and Markets Authority quietly updated its register, which now lists 57 other…

② Injective price focuses on a $7 rebound after bull run breakout and ETF filing update
After regaining key support, Injective is showing fresh bullish momentum, and analysts expect it could move higher if buying power continues to strengthen. Meanwhile, Canary Capital’s updated staked INJ ETF filing adds optimism, introducing higher staking transparency and regulatory measures.

③ Bitcoin profit/loss ratio falls to a 43-month low
Bitwise Chief Investment Officer Matt Hougan says the bottom is “closer than ever,” while Swan Bitcoin analysts advise investors to buy now at a discount rather than pay more later.

④ Pepe shares soar 12.16% as altcoins rebound — July 4 news
Pepe jumped 12.16% to $0.000003, topping the gainers list, while LAB fell 49.90% to $5.90, recording the largest drop. Altcoins performed mixed today. On July 4, altcoins rebounded, rising 16%.

⑤ NEAR price extends recovery as NEAR Protocol releases June performance statistics and milestones
Since the start of this month, the price of the NEAR protocol has surged by more than 20%, drawing attention again. With bullish momentum rebounding strongly, the gold price has recovered to above $2. The NEAR price surge came after NEAR Protocol released its June performance and statistics. Such a price reaction suggests…

⑥ Celestia targets $7.56 after bull breakout signal and V9 release
Celestia is building momentum as traders track strong technical signals and a potential breakout supported by the recent mainnet upgrade (improving network speed and capacity). The combination of price gains and infrastructure improvements strengthens market optimism, and analysts believe…

$BTC$BNB$ETH
INJ3.51%
BTC1.68%
PEPE1.37%
LAB0.64%
NEAR2.84%
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned